Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare ConferencePress release – No. 15 / 2026
- 腦動極光於《BMC Medicine》發表中國首個兒童認知障礙AI數字療法的最佳數字訓練劑量研究，填補了兒童訓練量效關係的國際空白，並進一步鞏固其在全球市場的領先地位香港, 2026年9月9日 - 脑动极光医疗科技有限公司（「 腦動極光 」或「 公司 」，連同其附屬公司統稱「集團」）（股份代號： 06681.HK ）今日欣然公佈公司的科研團隊和首都醫科大學附屬北京兒童醫院倪鑫教授團隊聯合開展的研究《Optimal doses of cognitive digital therapeutics for pediatric patients with cognitive impairments: A retrospective study based on big data》已於國際頂級綜合醫學期刊《BMC Medicine》（2025 Journal Impact Factor：8.7）發表。該研究是基於應用腦動極光AI數字療法系統的中國首個大規模定義兒童認知障礙患者年齡和性別特異性最佳數字訓練劑量的真實世界大數據研究，其結論清晰地指出受訓者的單日訓練超過8分鐘才有顯著提升，
- 腦動極光於《BMC Medicine》發表中國首個兒童認知障礙AI數字療法的最佳數字訓練劑量研究，填補了兒童訓練量效關係的國際空白，並進一步鞏固其在全球市場的領先地位香港, 2026年9月9日 - 脑动极光医疗科技有限公司（「腦動極光」或「公司」，連同其附屬公司統稱「集團」）（股份代號：06681.HK）今日欣然公佈公司的科研團隊和首都醫科大學附屬北京兒童醫院倪鑫教授團隊聯合開展的研究《Optimal doses of cognitive digital therapeutics for pediatric patients with cognitive impairments: A retrospective study based on big data》已於國際頂級綜合醫學期刊《BMC Medicine》（2025 Journal Impact Factor：8.7）發表。該研究是基於應用腦動極光AI數字療法系統的中國首個大規模定義兒童認知障礙患者年齡和性別特異性最佳數字訓練劑量的真實世界大數據研究，其結論清晰地指出受訓者的單日訓練超過8分鐘才有顯著提升，每天16-20分鐘對應最高認知表現，為整體人群最佳每日劑量。超過此範圍後，繼續延長單日訓練時間並未帶來額外顯著效益。 此臨床數據研究結論為未來精準的個體化認知數字療法干預提供了有力臨床證據，並為未來治療指南的制定提供了參考。 真實世界大數據助力未來認知訓練劑量的定義 上述研究是一項基於真實世界大數據的回顧性研究，納入2021至2025年間使用腦動極光的「腦功能信息管理平台軟件系統」（第二類醫療器械，湘械注准：20182210142）完成至少兩周訓練的38,526 名認知功能受損兒童和青少年（3-18歲），系統描繪了每日訓練時長、每周訓練頻率和總訓練周期三個維度的劑量－反應關係。平台包含123項由經典範式改編的任務，覆蓋感知覺、注意力、記憶力和執行功能四大認知領域。研究以平均認知指數(MCI)作為主要結果指標，反映訓練中的綜合任務表現。 該研究的主要成果，包括 整體人群最佳每日劑量：以每天0-4分鐘為基線，單日訓練超過8分鐘才有顯著提升，每天16-20分鐘對應最高認知表現，為整體人群最佳每日劑量。超過此範圍後，繼續延長單日訓練時間並未帶來額外顯著收益。 年齡與性別分層差異：四個亞組呈現出不同的最佳每日劑量與總劑量： 年齡組別 性別 最佳每日劑量 最佳總劑量 <10歲 男 16-20分鐘/天 6-7個月 <10歲 女 24-28分鐘/天 8-9個月 ≥10歲 男 20-24分鐘/天 4-5個月 ≥10歲 女 16-20分鐘/天 1-2個月 每周訓練頻率：四個亞組的最高認知表現均出現在每周7天訓練；多數亞組至少需要每周訓練5天才出現顯著改善。 總干預周期：無論年齡和性別，訓練超過1個月的兒童均較訓練不足1個月者表現出顯著認知改善。 參考文獻：Liu Y, Liang S, Liang A, et al. Optimal doses of cognitive digital therapeutics for pediatric patients with cognitive impairments: A retrospective study based on big data. BMC Medicine. 2026. DOI: 10.1186/s12916-026-05080-8. 腦動極光董事長譚錚表示：「我們十分高興在腦動極光科研團隊和首都醫科大學附屬北京兒童醫院倪鑫教授團隊共同努力下，為全球個體化兒童認知數字療法的持續優化提供了基於真實世界大數據的卓越研究。本研究基於38,526名兒童的真實世界數據，首次系統定義了不同年齡和性別的最佳數字訓練劑量，填補了全球兒童認知數字療法領域劑量－反應關係的研究空白，為個體化精準干預提供了循證依據。該成果發表於國際頂級綜合醫學期刊《 BMC Medicine》，體現了腦動極光在認知數字療法大規模真實世界數據研究領域的領先能力，進一步拓展了集團數字療法的循證證據版圖，覆蓋兒童認知障礙等多元人群。同時，該研究亦充分體現了腦動極光『產學研醫』融合模式的持續深化，不斷夯實推動集團長期發展戰略的底層科研和循證醫學實力，並進一步鞏固集團在全球認知障礙數字療法及兒科疾病數字療法領域的行業領先地位，為股東創造長期價值。」 關於脑动极光医疗科技有限公司 脑动极光医疗科技有限公司（「腦動極光」，股份代號：06681.HK）成立於2012年，並於2025年在香港聯交所主板上市。腦動極光是中國認知障礙數字療法市場的資深參與者，亦是中國首家將腦科學與先進的AI（人工智能）技術相結合，開發出針對認知障礙的醫療級數字療法產品的公司。公司的產品管線涵蓋由血管疾病、神經退行性疾病、精神障礙及兒童發育缺陷等誘發的廣泛的認知障礙的測評和干預。公司的核心產品，腦功能信息管理平台軟件系統是中國首個獲得監管批准的認知障礙數字療法產品。截至2026年6月30日，該核心產品已被納入中國30個省份的省級醫保報銷目錄。 欲瞭解更多資訊，請訪問 https://www.66nao.cn
- 脑动极光于《BMC Medicine》发表中国首个儿童认知障碍AI数字疗法的最佳数字训练剂量研究，填补了儿童训练量效关系的国际空白，并进一步巩固其在全球市场的领先地位香港, 2026年9月9日 - (亚太商讯) - 脑动极光医疗科技有限公司（「脑动极光」或「公司」，连同其附属公司统称「集团」）（股份代号：06681.HK）今日欣然公布公司的科研团队和首都医科大学附属北京儿童医院倪鑫教授团队联合开展的研究《Optimal doses of cognitive digital therapeutics for pediatric patients with cognitive impairments: A retrospective study based on big data》已于国际顶级综合医学期刊《BMC Medicine》（2025 Journal Impact Factor：8.7）发表。该研究是基于应用脑动极光AI数字疗法系统的中国首个大规模定义儿童认知障碍患者年龄和性别特异性最佳数字训练剂量的真实世界大数据研究，其结论清晰地指出受训者的单日训练超过8分钟才有显著提升，每天16-2
- 脑动极光于《BMC Medicine》发表中国首个儿童认知障碍AI数字疗法的最佳数字训练剂量研究，填补了儿童训练量效关系的国际空白，并进一步巩固其在全球市场的领先地位香港, 2026年9月9日 - (亚太商讯) - 脑动极光医疗科技有限公司（「脑动极光」或「公司」，连同其附属公司统称「集团」）（股份代号：06681.HK）今日欣然公布公司的科研团队和首都医科大学附属北京儿童医院倪鑫教授团队联合开展的研究《Optimal doses of cognitive digital therapeutics for pediatric patients with cognitive impairments: A retrospective study based on big data》已于国际顶级综合医学期刊《BMC Medicine》（2025 Journal Impact Factor：8.7）发表。该研究是基于应用脑动极光AI数字疗法系统的中国首个大规模定义儿童认知障碍患者年龄和性别特异性最佳数字训练剂量的真实世界大数据研究，其结论清晰地指出受训者的单日训练超过8分钟才有显著提升，每天16-20分钟对应最高认知表现，为整体人群最佳每日剂量。超过此范围后，继续延长单日训练时间并未带来额外显著效益。 此临床数据研究结论为未来精准的个体化认知数字疗法干预提供了有力临床证据，并为未来治疗指南的制定提供了参考。 真实世界大数据助力未来认知训练剂量的定义 上述研究是一项基于真实世界大数据的回顾性研究，纳入2021至2025年间使用脑动极光的「脑功能信息管理平台软件系统」（第二类医疗器械，湘械注准：20182210142）完成至少两周训练的38,526 名认知功能受损儿童和青少年（3-18岁），系统描绘了每日训练时长、每周训练频率和总训练周期三个维度的剂量－反应关系。平台包含123项由经典范式改编的任务，覆盖感知觉、注意力、记忆力和执行功能四大认知领域。研究以平均认知指数(MCI)作为主要结果指标，反映训练中的综合任务表现。 该研究的主要成果，包括 整体人群最佳每日剂量：以每天0-4分钟为基线，单日训练超过8分钟才有显著提升，每天16-20分钟对应最高认知表现，为整体人群最佳每日剂量。超过此范围后，继续延长单日训练时间并未带来额外显著收益。 年龄与性别分层差异：四个亚组呈现出不同的最佳每日剂量与总剂量： 年龄组别 性别 最佳每日剂量 最佳总剂量 <10岁 男 16-20分钟/天 6-7个月 <10岁 女 24-28分钟/天 8-9个月 ≥10岁 男 20-24分钟/天 4-5个月 ≥10岁 女 16-20分钟/天 1-2个月 每周训练频率：四个亚组的最高认知表现均出现在每周7天训练；多数亚组至少需要每周训练5天才出现显著改善。 总干预周期：无论年龄和性别，训练超过1个月的儿童均较训练不足1个月者表现出显著认知改善。 参考文献：Liu Y, Liang S, Liang A, et al. Optimal doses of cognitive digital therapeutics for pediatric patients with cognitive impairments: A retrospective study based on big data. BMC Medicine. 2026. DOI: 10.1186/s12916-026-05080-8. 脑动极光董事长谭铮表示：「我们十分高兴在脑动极光科研团队和首都医科大学附属北京儿童医院倪鑫教授团队共同努力下，为全球个体化儿童认知数字疗法的持续优化提供了基于真实世界大数据的卓越研究。本研究基于38,526名儿童的真实世界数据，首次系统定义了不同年龄和性别的最佳数字训练剂量，填补了全球儿童认知数字疗法领域剂量－反应关系的研究空白，为个体化精准干预提供了循证依据。该成果发表于国际顶级综合医学期刊《 BMC Medicine》，体现了脑动极光在认知数字疗法大规模真实世界数据研究领域的领先能力，进一步拓展了集团数字疗法的循证证据版图，覆盖儿童认知障碍等多元人群。同时，该研究亦充分体现了脑动极光『产学研医』融合模式的持续深化，不断夯实推动集团长期发展战略的底层科研和循证医学实力，并进一步巩固集团在全球认知障碍数字疗法及儿科疾病数字疗法领域的行业领先地位，为股东创造长期价值。」 关于脑动极光医疗科技有限公司 脑动极光医疗科技有限公司（「脑动极光」，股份代号：06681.HK）成立于2012年，并于2025年在香港联交所主板上市。脑动极光是中国认知障碍数字疗法市场的资深参与者，亦是中国首家将脑科学与先进的AI（人工智能）技术相结合，开发出针对认知障碍的医疗级数字疗法产品的公司。公司的产品管线涵盖由血管疾病、神经退行性疾病、精神障碍及儿童发育缺陷等诱发的广泛的认知障碍的测评和干预。公司的核心产品，脑功能信息管理平台软件系统是中国首个获得监管批准的认知障碍数字疗法产品。截至2026年6月30日，该核心产品已被纳入中国30个省份的省级医保报销目录。 欲了解更多信息，请访问 https://www.66nao.cn Copyright 2026 亚太商讯. All rights reserved. www.acnnewswire.com
- BrainAu Released China's First Significant Scientific Research Findings on Optimal Digital Training Doses of AI Cognitive Therapeutics for Pediatric Patients, Demonstrating the Dose-Response Relationship, Further Consolidating its Leading Position in the Global DTx MarketsHONG KONG, Sept 9, 2026 - China’s No.1 cognitive digital therapeutics company - BrainAurora Medical Technology Limited (“BrainAu”)(Stock code:06681.HK) is pleased to announce that the Company’s scientific research team and the team of Professor Ni Xin from Beijing Children’s Hospital, Capital Medical University has jointly published the research titled “Optimal doses of cognitive digital therapeutics for pediatric patients with cognitive impairments: A retrospective study based on big data” in BMC Medicine (2025 Journal Impact Factor: 8.7), a top international comprehensive medical journal. This study is China's first large-scale real-world big data study based on the BrainAu’s AI cognitive digital therapeutics, which defines age- and sex-specific optimal digital training doses for pediatric patients with cognitive impairment. Its conclusions clearly indicate that trainees achieved significant improvement only when daily training exceeded 8 minutes, with 16 to 20 minutes per day corresponding to the highest cognitive performance, representing the optimal daily dose for the overall population. Beyond this range, further extending daily training duration did not yield additional significant benefits. The result findings of the real-world big data study provide strong evidence for individualized precise cognitive digital therapeutic interventions and serve as a reference for the formulation of future treatment guidelines. Real-world Big Data Helps Define Future Cognitive Training Dosages As a retrospective study based on real-world big data, this study included 38,526 children and adolescents (aged from 3 to 18 years) with cognitive impairment who used the BrainAu’s “Brain Function Information Management Platform Software System” (Class II medical device, Registration Certificate No.: Xiang Xie Zhu Zhun 20182210142) and completed at least two weeks of training between 2021 and 2025, systematically characterized the dose-response relationship across three dimensions: daily training duration, weekly training frequency, and total training cycle. The platform contains 123 tasks adapted from classic paradigms, covering four major cognitive domains, namely perception, attention, memory, and executive function. The Mean Cognitive Index (MCI) adopted by the study as the primary outcome measure reflects comprehensive task performance during training. The study achieved the following positive and outstanding result findings, including: Optimal daily dose for the overall population: with 0 to 4 minutes per day as the baseline, significant improvement was observed only when daily training exceeded 8 minutes, with 16 to 20 minutes per day corresponding to the highest cognitive performance, representing the optimal daily dose for the overall population. Beyond this range, further extending daily training duration did not yield additional significant benefits. Age-and sex-stratified differences: the four subgroups demonstrated different optimal daily doses and total doses: Age Group Gender Optimal Daily Dose Optimal Total Dose <10 years old Male 16 to 20 minutes/day 6 to 7 months <10 years old Female 24 to 28 minutes/day 8 to 9 months ≥10 years old Male 20 to 24 minutes/day 4 to 5 months ≥10 years old Female 16 to 20 minutes/day 1 to 2 months Weekly training frequency: the highest cognitive performance across all four subgroups was observed with 7 days of training per week; for most subgroups, significant improvement was observed only when training was conducted on at least 5 days per week. Total intervention cycle: regardless of age and gender, children who received training for more than 1 month demonstrated significant cognitive improvement compared to those who received training for less than 1 month. Reference: Liu Y, Liang S, Liang A, et al. Optimal doses of cognitive digital therapeutics for pediatric patients with cognitive impairments: A retrospective study based on big data. BMC Medicine. 2026. DOI: 10.1186/s12916-026-05080-8. Mr. Tan Zheng, Chairman of BrainAu, concluded: “We are delighted that, through the joint efforts of our scientific research team and the team of Professor Ni Xin from Beijing Children’s Hospital, Capital Medical University, we have provided outstanding research findings based on real-world big data for the continuous optimization of personalized digital cognitive therapeutics for pediatric patients with cognitive impairments worldwide. Based on real-world data of 38,526 children, this study systematically defined for the first time the optimal digital training doses for different ages and genders, filled the research gap in the dose-response relationship in the field of pediatric cognitive digital therapeutics and provided an evidence-based foundation for individualized precise intervention. The publication of these findings in the top international comprehensive medical journal BMC Medicine reflects the Group’s leading capabilities in the field of large-scale real-world data research on cognitive digital therapeutics, thereby further expanding the Group’s evidence-based landscape for digital therapeutics to cover diverse populations such as pediatric cognitive impairment. At the same time, this study also fully reflects the ongoing deepening of the Group’s “industry-academia-research-medicine” integration model shall continue to reinforce our underlying scientific-research and evidence-based medicine capabilities underpinning the Group’s long-term development strategy, as well as will further consolidate the Group’s industry-leading position in digital therapeutics for cognitive impairment and digital therapeutics for pediatric diseases, creating long-term value to shareholders.” About BrainAurora Medical Technology Limited BrainAurora Medical Technology Limited (“BrainAu”, HKEX : 06681.HK) was founded in 2012 and listed on the Main Board of Hong Kong Stock Exchange in 2025. BrainAu is a seasoned player in China’s cognitive impairment digital therapeutics (the “DTx”) market and is the first company in China that has developed a medical-grade DTx product for cognitive impairment, combining brain science with advanced artificial intelligence (the “AI”) technologies. The Company’s product pipeline covers both the assessment and intervention of a broad range of cognitive impairments induced by vascular diseases, neurodegenerative diseases, psychiatric disorders, and child development deficiencies, among others. The Company’s core product, namely the Brain Function Information Management Platform Software System is the first cognitive impairment DTx product that has obtained regulatory approval in China. As of the date of 30 June 2026, the core product had been included in the provincial health insurance reimbursement lists of 30 provinces in China. For more information, please visit https://www.66nao.cn
- Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech SummitNUTRIBAND CEO, GARETH SHERIDAN TO ATTEND THE INAUGURAL NASDAQ LIFE SCIENCES ADVISORY BOARD (LAB) BIOTECH SUMMIT
- Halia TherapeuticsHalia Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare ConferenceHalia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class therapies targeting inflammasome-driven disease biology, today announced that the Company plans to present at the Morgan Stanley 24th Annual Global...
- Peptide Drug Conjugates Market Size to Hit USD 15.05 Billion by 2035 at a CAGR of 14.6% - SNS InsiderU.S. Peptide Drug Conjugates Market to Reach USD 5.81 Billion and Europe USD 3.72 Billion by 2035 as Radioligand Expansion, Antigen-Independent Platforms, and Oncology Demand Drive Growth.
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
- Jasper Therapeutics, Inc.Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceJasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that management will participate at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026 in New York, NY.
- Adagene Inc. SAN DIEGO andAdagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate CandidatesAdagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis, Inc. (“Exelixis”).